Journal
ANTIVIRAL RESEARCH
Volume 101, Issue -, Pages 26-29Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2013.10.012
Keywords
Henipavirus; Nipah; Vaccine; VSV; Single-dose; Hamster
Categories
Funding
- NIH Northeast Biodefense Center Grant [U54-AI057158]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057158, T32AI007610] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Nipah virus (NiV) continues to cause outbreaks of fatal human encephalitis due to spillover from its bat reservoir. We determined that a single dose of replication-defective vesicular stomatitis virus (VSV)-based vaccine vectors expressing either the NiV fusion (F) or attachment (G) glycoproteins protected hamsters from over 1000 times LD50 NiV challenge. This highly effective single-dose protection coupled with an enhanced safety profile makes these candidates ideal for potential use in livestock and humans. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
